menu
    • menu
    [{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Azidus","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Blau Farmaceutica","highestDevelopmentStatusID":"6","companyTruncated":"Blau Farmaceutica \/ Blau Farmaceutica"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blau Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Undisclosed","graph2":"Phase I","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blau Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Azidus","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"BRAZIL","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Blau Farmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Blau Farmaceutica \/ Blau Farmaceutica"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Azidus","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"BRAZIL","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Blau Farmaceutica","highestDevelopmentStatusID":"10","companyTruncated":"Blau Farmaceutica \/ Blau Farmaceutica"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blau Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Blau Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Filgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blau Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Blau Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Blau Farmaceutica","sponsor":"JSR Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"Epoetin Alpha","moa":"Undisclosed","graph1":"Hematology","graph2":"Approved FDF","graph3":"Blau Farmaceutica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blau Farmaceutica \/ Blau Farmaceutica","highestDevelopmentStatusID":"15","companyTruncated":"Blau Farmaceutica \/ Blau Farmaceutica"}]

    Find Clinical Drug Pipeline Developments & Deals by Blau Farmaceutica

    Menu

    Blau Farmaceutica

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration

                            Details : Heparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2023

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration

                            Details : Heparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 29, 2023

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Filgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness and Safety Study of Filgrastine® in Patientes With Breast Cancer Treated With Myelotoxic Chem...

                            Details : Filgrastim is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 29, 2023

                            Lead Product(s) : Filgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asses the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood in Childrens

                            Details : Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            January 30, 2023

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Epoetin Alpha

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Recipient : JSR Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs

                            Details : The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders.

                            Product Name : rHuEPO

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            October 25, 2022

                            Lead Product(s) : Epoetin Alpha

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Recipient : JSR Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Recipient : Azidus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

                            Details : Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            June 28, 2018

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Recipient : Azidus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Recipient : Azidus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.

                            Details : Epoetin Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            September 28, 2012

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Recipient : Azidus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed

                            Blau Farmaceutica

                            Brazil arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : Azidus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration

                            Details : Heparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 25, 2012

                            Lead Product(s) : Heparin Sodium

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : Azidus

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth